Viking Therapeutics Stock Year To Date Return
| VKTX Stock | USD 42.25 0.76 1.83% |
Viking Therapeutics fundamentals help investors to digest information that contributes to Viking Therapeutics' financial success or failures. It also enables traders to predict the movement of Viking Stock. The fundamental analysis module provides a way to measure Viking Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Viking Therapeutics stock.
Viking |
Viking Therapeutics Company Year To Date Return Analysis
Viking Therapeutics' Year to Date Return (YTD) is the total return generated from holding a security from the beginning of the current fiscal year. In other words, YTD Return represents the capital appreciation of your investments from the start of the current fiscal year.
More About Year To Date Return | All Equity Analysis
YTD Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Year-To-Date typically refers to a period starting from the beginning of the current year and continuing up to the present day. Investors should becareful when comparing YTD ratios if not much of the year has occurred as research shows that YTD measures are more sensitive to early periods than late.
| Competition |
As per the company's disclosures, Viking Therapeutics has a Year To Date Return of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Viking Year To Date Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Viking Therapeutics' direct or indirect competition against its Year To Date Return to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Viking Therapeutics could also be used in its relative valuation, which is a method of valuing Viking Therapeutics by comparing valuation metrics of similar companies.Viking Therapeutics is currently under evaluation in year to date return category among its peers.
Viking Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Viking Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Viking Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Viking Fundamentals
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.13 | ||||
| Current Valuation | 3.78 B | ||||
| Shares Outstanding | 111.44 M | ||||
| Shares Owned By Insiders | 5.96 % | ||||
| Shares Owned By Institutions | 75.44 % | ||||
| Number Of Shares Shorted | 18.07 M | ||||
| Price To Earning | (3.17) X | ||||
| Price To Book | 5.17 X | ||||
| EBITDA | (100.83 M) | ||||
| Net Income | (85.89 M) | ||||
| Cash And Equivalents | 155.02 M | ||||
| Cash Per Share | 2.02 X | ||||
| Total Debt | 1.26 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 11.74 X | ||||
| Book Value Per Share | 8.18 X | ||||
| Cash Flow From Operations | (73.38 M) | ||||
| Short Ratio | 3.20 X | ||||
| Earnings Per Share | (0.94) X | ||||
| Price To Earnings To Growth | (0.03) X | ||||
| Target Price | 110.0 | ||||
| Number Of Employees | 30 | ||||
| Beta | 0.99 | ||||
| Market Capitalization | 4.71 B | ||||
| Total Asset | 368.49 M | ||||
| Retained Earnings | (377.94 M) | ||||
| Working Capital | 348.09 M | ||||
| Current Asset | 15.2 M | ||||
| Current Liabilities | 1.98 M | ||||
| Net Asset | 368.49 M |
About Viking Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Viking Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Viking Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Viking Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Viking Stock Analysis
When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.